SENSOR AUGMENTED
PUMP THERAPY
SENSOR AUGMENTED PUMP THERAPY
WHAT IS IT?
Sensor Augmented Pump Therapy such as the MiniMedTM 640G system with SmartGuardTM has been shown to prevent hypoglycaemia1 and deliver better glucose control for patients with diabetes2,3
There are three main components to a Sensor Augmented Pump:
- An insulin pump such as the MiniMed 640G
- A glucose sensor- EnliteTM
- A transmitter- GuardianTM 2 Link
All Sensor Augmented Pumps allow patients to see their glucose levels on their insulin pump or on a separate device and alerts them when their glucose levels are rising or falling. However Medtronic Sensor Augmented Pumps are the only systems on the market with an automatic suspend feature called SmartGuard.
HOW A SENSOR AUGMENTED PUMP WORKS
The glucose sensor Enlite is inserted in to the subcutaneous tissue using the intended insertion device. The retractable needle is then removed, leaving a flexible electrode under the skin.
The sensor continuously converts tiny amounts of glucose from the interstitial fluid in to an electrical signal. The system then uses these signals to provide sensor glucose values. The insulin pump then acts as a receiver of Continuous Glucose Monitoring (CGM) data sent wirelessly from the sensor by the transmitter.
ADVANCED PROTECTION FROM HYPOGLYCAEMIA
The MiniMed 640G system with SmartGuard technology is the only system clinically proven to prevent hypoglycaemia1
SmartGuard within the MiniMed 640G Sensor Augmented Pump system works by suspending insulin when sensor glucose is approaching a pre-set low limit*. SmartGuard will resume basal insulin automatically if sensor glucose recovers.
WHAT ARE THE BENEFITS OF SENSOR AUGMENTED PUMP THERAPY
The MiniMed 640G system with SmartGuard technology is the only system clinically proven to prevent hypoglycaemia1. In real life the MiniMed 640G system with SmartGuard technology has been shown to prevent sensor glucose from hitting the low limit of 3.3 mmol/mol 75% of the time4
Sensor Augmented Pump therapy reduces HbA1c and improves glycaemic control. Several randomised controlled trials showed that CGM contributed to:
- Up to 1% HbA1c reduction with no increase in hypoglycaemia5
- Tighter glycaemic control6
- Achieve better control over their diabetes
The advantages of CGM over traditional fingerstick testing and HbA1c testing are well documented.
Research shows that:
- 60% of glucose lows may not be revealed with fingerstick testing alone7
- CGM identifies four times as many serious glucose incidents as self-monitoring of blood glucose (SMBG)8
- CGM can significantly reduce HbA1c levels by up to 1% when compared with fingerstick testing alone9
HYPOGLYCAEMIA IS CHALLENGING FOR GLYCAEMIC CONTROL2 AND HEALTHCARE COSTS3
 |
 |
 |
 |
The MiniMed 640G system with SmartGuard technology is the only system clinically proven to prevent hypoglycaemia1
1 Choudhary, P. DTT. 2016, Vol 18, (5).
2 Bergenstal RM, Tamborlane WV, Ahmann A, et al. The STAR 3 Study Group. Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. N Engl J Med. 2010;363(4):311-320.
3 Garg S, Brazg RL, Bailey TS , et al. Reduction in duration of hypoglycemia by automatic suspension of insulin delivery: the in-clinic ASPIRE study. Diabetes Tech Ther. 2012;14(3):205-209.
4 Data on file- SmartGuard real life evaluated using the voluntary MiniMed 640G uploads to CareLink Personal from Jan. 13th 2015 to Jan. 14th 2016
5 Raccah D, Sulmont V, Resnik Y, et al. Incremental value of continuous glucose monitoring when starting pump therapy in patients with poorly controlled type 1 diabetes: the RealTrend Study. Diabetes Care. 2009;32(12):2245-2250
6 J. C. Pickup and A. J. Sutton Severe hypoglycaemia and glycemic control in Type 1 diabetes: meta-analysis of multiple daily insulin injections compared with continuous subcutaneous insulin infusion Diabetic Medicine 2008 :25, 765–774
7 Pitzer KR, Desai S, Dunn T, et al. Detection of hypoglycemia with the GlucoWatch biographer. Diabetes Care. 2001;24(5):881-885.
8 Kaufman FR, et al. Diabetes Care. 2001;24(12):2030-2034
9 Raccah D, Sulmont V, Resnik Y, et al. Incremental value of continuous glucose monitoring when starting pump therapy in patients with poorly controlled type 1 diabetes: the RealTrend Study. Diabetes Care. 2009;32(12):2245-2250
Recommended Information
THE MINIMED™ 640G SYSTEM
Our most advanced insulin pump, with SmartGuard™ technology
MINIMED MIO™ INFUSION SETS
Recognising the needs of individual with tailored technology
REIMBURSEMENT STATUS
Estimated level of funding/reimbursement for the CSII & CGM in Europe